The booming business with corona tests makes the laboratory service provider Synlab even more optimistic for the current year. According to a statement on Thursday evening, management is aiming for sales growth of up to a quarter to 2021 to 3,2 billion euros in 3,3. So far, there has only been talk of more than 3,0 billion euros. Adjusted operating earnings before interest, taxes, depreciation and amortization (Ebitda) are expected to climb by more than a third to at least 925 million euros.
In addition to various tests for the Sars-CoV-2 virus, Synlab also has numerous other offers relating to laboratory diagnostics, for example for clinics and doctors. The company also has a smaller veterinary branch.
Synlab only went public at the end of April. The shares, which were issued at 18 euros, rose to a record high of 21,46 euros on the second day of trading before they went into reverse. Investors worry that the growth of the group depends to a large extent on the corona tests. If at some point it were no longer necessary, an important business would collapse, which would be difficult to absorb, according to fears.